When would you use PSMA PET over conventional imaging for prostate cancer?

So far, most (but not all) prospective data for molecular imaging has been obtained in the setting of biochemical recurrence and that is where I have used it most outside of trials.

In the primary disease setting, some trials examined the utility to detect nodal and distant disease (like OSPREY publi...

If money were no object, the short answer is, every time, in the setting of recurrence or in the setting of high risk or very high risk disease based on the ProPSMA trial (Hofman et al., PMID 32209449) and the Appropriate Use Criteria put out by the Society for Nuclear Medicine and Molecular Imaging...